Istanbul Arel University
Istanbul, Zeytinburnu, 34015, Turkey (Türkiye)
NCT Number: NCT07435441
This study aims to evaluate the validity and reliability of the Turkish version of the Bolus Residue Scale (BRS) in patients with acute stroke. The study has a methodological, observational, and cross-sectional design. Videofluoroscopic swallowing study (VFSS) recordings will be scored independently by trained raters using the BRS. Psychometric properties including construct validity, criterion validity, inter-rater and intra-rater reliability will be analyzed.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Istanbul, Zeytinburnu, 34015, Turkey (Türkiye)
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This study does not involve any therapeutic, behavioral, or procedural intervention. All assessments were performed as part of routine clinical care, and no changes were made to standard treatment or clinical management.
Time frame: Baseline (during videofluoroscopic swallowing study assessment)
The Bolus Residue Scale (BRS) Turkish version is a videofluoroscopic swallowing assessment tool used to evaluate the severity of pharyngeal residue following swallowing.
The scale consists of six ordinal levels, ranging from Grade 1 (no residue) to Grade 6 (severe residue) based on the presence and extent of bolus residue in the pharynx.
Higher scores indicate greater pharyngeal residue severity and poorer swallowing efficiency.
Time frame: Baseline (during videofluoroscopic swallowing study assessment)
The Penetration-Aspiration Scale (PAS) is an 8-point ordinal scale used during videofluoroscopic swallowing assessment to evaluate the severity of airway invasion.
The scale ranges from Score 1 (material does not enter the airway) to Score 8 (material enters the airway, passes below the vocal folds, and no effort is made to eject it).
Higher scores indicate more severe penetration or aspiration and poorer airway protection during swallowing.
Time frame: Baseline (during videofluoroscopic swallowing study assessment)
The Yale Pharyngeal Residue Severity Rating Scale (YPRSRS) is a 5-point ordinal scale used to quantify the severity of pharyngeal residue during videofluoroscopic swallowing study (VFSS).
Residue severity is rated separately for the valleculae and pyriform sinuses, with scores ranging from 0 (no residue) to 4 (severe residue) based on the amount of bolus residue remaining after swallowing.
Higher scores indicate greater pharyngeal residue and more severe swallowing impairment.
Time frame: Baseline (during videofluoroscopic swallowing study assessment)
The Functional Oral Intake Scale (FOIS) is a 7-level ordinal scale used to classify an individual's level of oral intake in patients with dysphagia.
The scale ranges from Level 1 (nothing by mouth) to Level 7 (total oral diet with no restrictions), reflecting the degree of functional oral intake.
Higher FOIS levels indicate better oral intake ability and improved swallowing function.
Istanbul Arel University
Other
Turkish Validity and Reliability of the Bolus Residue Scale (BRS) in Patients With Acute Stroke
Acronym: BRS-TR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06301542
Post-stroke
Boston, Massachusetts, United States
View Trial DetailsNCT07213180
Post-stroke
Ploemeur, Brittany Region, France
View Trial DetailsNCT02091739
Basal Ganglia Diseases, Brain Diseases
Bonn, Germany
View Trial DetailsNCT07616050
Amyotrophic Lateral Sclerosis, Autoimmune Diseases
Bari, Italy
View Trial Details